SOAT1 and Alzheimer disease: Topical JAK inhibitors like 1.5% ruxolitinib reduces IL-4 and IL-13 cytokine signaling by inhibiting the JAK-STAT intracellular transduction pathway and the American Academy of Dermatology strongly recommends topical JAK inhibitors for the treatment of AD, however limited long-term safety data is available [45].